Home
Voyager Therapeutics

Voyager Therapeutics Market Share Analysis for November 2025

Health > Biotechnology and Pharmaceuticals

Domainvoyagertherapeutics.com

Year Founded2014

Employees51 - 200

Annual Revenue$25M - $50M

Voyager Therapeutics

Voyager Therapeutics (including company regionals)

voyagertherapeutics.com

See more website traffic and engagement information

Voyager Therapeutics Revenue up to November 2025 is 25M - 50M

revenue generated by Voyager Therapeutics top domains

Voyager Therapeutics top domains revenue over 3 years

Revenue for Voyager Therapeutics top domains

voyagertherapeutics.com25M - 50M

See more with Sales Intelligence

Total visits to Voyager Therapeutics's top domains

Understand Voyager Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

voyagertherapeutics.com10.5K

See more with Sales Intelligence

Avg. visit duration in Voyager Therapeutics's top domains

Analyze Voyager Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

voyagertherapeutics.com00:00:29

See more with Sales Intelligence

Avg. pageviews on Voyager Therapeutics's top domains

See how Voyager Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

voyagertherapeutics.com1.57

See more with Sales Intelligence

Voyager Therapeutics top competitors by domain

Top similar sites in November 2025, ranked by their affinity

akouos.comCompany NameAkouosEmployees51 - 200HQUnited States, Massachusetts, BostonAnnual revenue$25M - $50MTotal visits2.6KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Voyager Therapeutics

These are the website technologies, by industry, used by Voyager Therapeutics top domains

Payment & Currencies (10)

Cart Functionality

eCommerce (6)

OpenCart

Widget (3)

Twemoji

Advertising (2)

PubMatic

More Technologies

9

See all

News & Signals from Voyager Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsVoyager Therapeutics, Inc. is developing small-molecule therapies for ALS and FTD.Transition Bio and Voyager Therapeutics partner to develop small-molecule therapies for ALS and FTD.

NewsVoyager Therapeutics, Inc. launches programme that modulates the expression of apolipoprotein E.Voyager Therapeutics has added a new programme that modulates the expression of apolipoprotein E (APOE), the strongest genetic risk factor for Alzheimer's disease (AD).

NewsVoyager Therapeutics, Inc. attends event H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference.LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) - Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference.